MDxHealth SA (MDXH)
| Market Cap | 57.59M -71.7% |
| Revenue (ttm) | 114.02M +22.6% |
| Net Income | -37.34M |
| EPS | -0.74 |
| Shares Out | 95.42M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 791,496 |
| Open | 0.6400 |
| Previous Close | 0.6317 |
| Day's Range | 0.5760 - 0.6499 |
| 52-Week Range | 0.4000 - 5.3300 |
| Beta | -518,218.96 |
| Analysts | Buy |
| Price Target | 1.80 (+198.21%) |
| Earnings Date | Nov 12, 2026 |
About MDXH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. The company’s testing solutions include Confirm mdx for prostate cancer tissue test that validates epigenetic test that guides the detection of occult prostate cancer on a patient’s previously biopsied negative tissue; ExoD, a non-invasive urine test to assess risk of having clinically prostate cancer; and Resolve mdx for urinary tract infection that identifies personalized effective antibiotic options a... [Read more]
Financial Performance
In 2025, MDxHealth's revenue was $107.88 million, an increase of 19.80% compared to the previous year's $90.05 million. Losses were -$33.52 million, -11.95% less than in 2024.
Financial StatementsAnalyst Summary
According to 6 analysts, the average rating for MDXH stock is "Buy." The 12-month stock price target is $1.8, which is an increase of 198.21% from the latest price.
News
MDxHealth reports preliminary Q3 revenue $22.7M, consensus $24.55M
Michael McGarrity, CEO of mdxhealth (MDXH), commented: “Third quarter revenue fell short of our expectations. Following the discontinuation of Resolve mdx, we experienced unexpected turnover within ou...
MDxHealth suspends FY26 revenue guidance of $110M-$115M
The company said, “Although this led to an interruption in the progress we reported in Q2, we are focused on fortifying impacted territories and returning to consistent execution. Importantly, we…
MDxHealth price target lowered to $2 from $4 at BTIG
BTIG lowered the firm’s price target on MDxHealth (MDXH) to $2 from $4 and keeps a Buy rating on the shares. The firm is updating its model after the company…
MDxHealth reports Q2 EPS (18c) vs. (14c) last year
Reports Q2 revenue $27.21M vs. $23.39M last year. Michael K. McGarrity, CEO of mdxhealth (MDXH), commented: “We delivered sequential revenue growth of $3.3 million from Q1 to Q2, establishing a…
MDxHealth price target lowered to $3 from $5 at Lake Street
Lake Street lowered the firm’s price target on MDxHealth (MDXH) to $3 from $5 and keeps a Buy rating on the shares after the company announced Q2 results and reiterated…
MDxHealth Earnings Call Transcript: Q2 2026
Q2 2026 saw a 16% year-over-year revenue increase and the largest sequential growth in company history, driven by a renewed focus on core urology diagnostics after discontinuing the Resolve UTI business. Guidance for $110–$115 million in 2026 revenue and a return to adjusted EBITDA profitability was reaffirmed.
MDxHealth Earnings release: Q2 2026
MDxHealth released its Q2 2026 earnings on August 13, 2026, summarizing the period's financial results.
Mdxhealth Reports Second Quarter 2026 Financial Results
Second quarter r evenue gr owth of 1 6 % to $ 2 7 . 2 million Conference call with Q&A today at 4 : 3 0 PM EST / 22 : 30 CET
MDxHealth Slides: Corporate presentation
MDxHealth has posted slides in relation to its latest quarterly earnings report, which was published on August 13, 2026.
Mdxhealth to Release Second Quarter 2026 Financial Results on August 13
Company to Host Conference Call with Live Q&A, August 13, 2026, at 4:30pm ET / 22:30 CET IRVINE, California – July 30, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH), a leading precision diagnosti...
MDxHealth receives noncompliance notification from Nasdaq
Mdxhealth (MDXH) announced that the company received an additional notification letter from Nasdaq related to the recent reduction in the price for the company’s ordinary shares. The initial notice, r...
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Market Value of Listed Securities Deficiency IRVINE, California – July 24, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the ...
MDxHealth receives noncompliance letter from Nasdsaq
Mdxhealth (MDXH) announced that the company received a notification letter from Nasdaq, notifying the company that it is not in compliance with the minimum bid price requirement set forth in…
Mdxhealth Announces Receipt of Nasdaq Notification Regarding Minimum Bid Price Deficiency
IRVINE, California – July 2, 2026 (GlobeNewswire) – Mdxhealth SA (NASDAQ: MDXH) (the "Company" or "mdxhealth"), a leader in urology-focused precision diagnostics, today announced that the Company rece...
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial
Mdxhealth Announces Peer-Reviewed Publication of Oxford GPS-ProMPT Study in European Urology Oncology, Establishing Scientific Foundation for the Landmark GPS-ProtecT Randomized Controlled Trial IRVIN...
MDxHealth Slides: Corporate presentation
MDxHealth has posted slides in relation to its latest quarterly earnings report, which was published on June 1, 2026.
MDxHealth price target lowered to $5 from $9 at Lake Street
Lake Street lowered the firm’s price target on MDxHealth (MDXH) to $5 from $9 and keeps a Buy rating on the shares. MDxHealth announced its Q1 results and the discontinuation…
MDxHealth price target lowered to $1.50 from $7 at TD Cowen
TD Cowen analyst Dan Brennan lowered the firm’s price target on MDxHealth (MDXH) to $1.50 from $7 and keeps a Buy rating on the shares. The firm said 1Q was…
MDxHealth downgraded to Market Perform from Outperform at William Blair
William Blair downgraded MDxHealth (MDXH) to Market Perform from Outperform without a price target The company’s Q1 revenue came in well below expectations and its full-year revenue guidance was cut…
MDxHealth price target lowered to $4 from $7 at BTIG
BTIG lowered the firm’s price target on MDxHealth (MDXH) to $4 from $7 and keeps a Buy rating on the shares after its Q1 miss and “material guidedown for 2026”.
MDxHealth to exit the Resolve mdx business
As part of its Q1 results announcement last night, the company stated: “On April 20, 2026, the Company received a Medicare contractor recoupment decision from Novitas Solutions totaling approximately ...
MDxHealth sees FY26 revenue $110M-$115M, consensus $118.6M
The company stated: “By streamlining our operations and removing the reimbursement volatility associated with Resolve, we are effectively resetting our growth trajectory for the remainder of the year....
MDxHealth Earnings Call Transcript: Q1 2026
Revenue for core prostate cancer diagnostics grew 11% year-over-year, with updated 2026 guidance of $110–$115 million (20–26% growth). The company exited the Resolve UTI business due to reimbursement uncertainty and is focusing on AI-driven innovation and operational efficiency.
MDxHealth Earnings release: Q1 2026
MDxHealth released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
MDxHealth reports Q1 EPS (17c) vs. (19c) last year
Reports Q1 revenue $27.39M, consensus $26.19M. Michael McGarrity, CEO of mdxhealth (MDXH), commented: “As we prioritized the integration of our recently acquired ExoDx business and to allow for renewe...